Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout

By The Northwire Desk — AI Analysis Apr 22, 2026 · 07:00 EPRX · 9.63 EUPRAXIA PHARMACEUTICALS INC. J
Executive Summary
  • Most Recent Release (April 21, 2026): Eupraxia reported 36-week clinical data from Cohort 9 (highest dose: 20 x 8 mg) in the RESOLVE Phase 1b/2a trial for eosinophilic esophagitis (EoE).
    • Efficacy: 66% clinical remission rate maintained from week 8 through week 36. Peak Eosinophil Count reduced by 72%. Tissue health showed significant reduction in Stage (-0.59) and Grade (-0.53).
    • Safety: No drug-related Serious Adverse Events (SAEs) or steroid-related side effects (candidiasis, adrenal insufficiency) across >230 patient-months of follow-up.
    • Pipeline: Phase 2b randomized placebo-controlled trial recruiting for 120mg and 160mg doses; top-line data expected Q4 2026.
  • Conference Announcement (April 22, 2026): Company will present four abstracts at Digestive Disease Week (DDW) in Chicago featuring the RESOLVE trial data. A virtual investor event is scheduled for May 4, 2026.
  • Historical Context: This follows positive tissue health data released Jan 8, 2026, and symptom data from March 17, 2026. The progression shows consistent durability of response over time (52-week data in Nov 2025 -> 36-week data Apr 2026).
  • Financials: Q4 2025 results showed a net loss of $16.7M but cash position strengthened to $80.5M following a Feb 20, 2026 public offering ($63.2M gross proceeds). Runway extends into H2 2028.
Material Impact
  • Expectation vs. Reality: The clinical data aligns with previous projections and guidance provided in January and March releases. It confirms the durability of the highest dose cohort without introducing unexpected safety concerns or efficacy misses.
  • Market Impact: While positive, this is a routine milestone update for a Phase 1b/2a biotech program. The market has likely priced in the high probability of success given the consistent trend over the last six months (Nov '25 to Apr '26). It does not constitute a "Game Changer" as it validates existing expectations rather than revealing new, unanticipated upside (e.g., Phase 3 approval or breakthrough designation).
  • Risk Mitigation: The primary value here is risk reduction. Confirming no SAEs and no steroid-related side effects at the highest dose reduces binary risk ahead of the Phase 2b top-line readout in Q4 2026.
  • Catalyst Timing: The next material catalyst is the Phase 2b top-line data expected in Q4 2026. Current news serves as a confidence builder for that event but does not trigger immediate re-rating of the stock to new highs.
EPRX · Price
Company Overview
  • Company: Eupraxia Pharmaceuticals Inc. (EPRX).
  • Flagship Project: EP-104GI for Eosinophilic Esophagitis (EoE).
  • Mechanism of Action: Long-acting submucosal corticosteroid formulation designed for local delivery via injection into esophageal tissues. Aims to address inflammation and fibrosis with a single administration procedure.
  • Development Stage: Phase 1b/2a RESOLVE trial (dose escalation) transitioning to Phase 2b (randomized placebo-controlled).
  • Indications: Primary focus on EoE; potential expansion into esophageal strictures, fibrostenotic Crohn's disease, and Barrett's esophagus.
Read the original news release →

More from EUPRAXIA PHARMACEUTICALS INC. J

May 12, 2026 · 17:00

Eupraxia Pharmaceuticals Secures H2 2028 Runway with Strong Clinical Data, But Phase 2b Catalyst Remains Key

Earnings May 06, 2026 · 07:00

Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst

Other May 05, 2026 · 07:00

Eupraxia Confirms Dose-Response in EoE Trial; Phase 2b Data Due Q4

Other Apr 21, 2026 · 07:00

Eupraxia Durability Data Validates Lead Candidate, Yet Phase 2b Timing Shifts to Q4

Other Mar 17, 2026 · 12:41

Eupraxia posts 24-week data in high-dose Resolve cohort

Other Mar 17, 2026 · 07:00

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Other